- Investor's Business Daily•16 hours ago
Exelixis is teaming up with Bristol-Myers Squibb and Roche to test its Cabometyx and their immuno-oncology drugs in liver and bladder cancer.
- American City Business Journals•23 hours ago
A Delaware-based biopharmaceutical company is headed to the S&P 500, a change that will become effective at the start of trading on Tuesday. Incyte (INCY) will replace Spectra Energy Corp. (SE) on the biotechnology sub-industry index . The announced shift came a day after the Wilmington biopharma firm and University of Pennsylvania announced a new research alliance that will focus on assessing new cancer treatments under development and advancing immunotherapy to fight cancer.
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||133.45 x 1000|
|Ask||135.30 x 1000|
|Day's Range||130.25 - 134.96|
|52 Week Range||60.30 - 134.97|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||248.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|